NZ606236A - Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease - Google Patents
Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver diseaseInfo
- Publication number
- NZ606236A NZ606236A NZ606236A NZ60623611A NZ606236A NZ 606236 A NZ606236 A NZ 606236A NZ 606236 A NZ606236 A NZ 606236A NZ 60623611 A NZ60623611 A NZ 60623611A NZ 606236 A NZ606236 A NZ 606236A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- prevention
- treatment
- adenovirus
- fatty liver
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 241000701161 unidentified adenovirus Species 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000005976 liver dysfunction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36244310P | 2010-07-08 | 2010-07-08 | |
| PCT/US2011/043338 WO2012006512A1 (en) | 2010-07-08 | 2011-07-08 | Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ606236A true NZ606236A (en) | 2014-09-26 |
Family
ID=44629893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ606236A NZ606236A (en) | 2010-07-08 | 2011-07-08 | Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8951980B2 (enExample) |
| EP (1) | EP2590665B1 (enExample) |
| JP (1) | JP5965397B2 (enExample) |
| KR (1) | KR101831638B1 (enExample) |
| CN (1) | CN103052397B (enExample) |
| AU (1) | AU2011274537B9 (enExample) |
| CA (1) | CA2803787C (enExample) |
| ES (1) | ES2550962T3 (enExample) |
| NZ (1) | NZ606236A (enExample) |
| TW (1) | TWI531650B (enExample) |
| WO (1) | WO2012006512A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014062794A1 (en) | 2012-10-17 | 2014-04-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for improving glucose uptake |
| US9354963B2 (en) * | 2014-02-26 | 2016-05-31 | Microsoft Technology Licensing, Llc | Service metric analysis from structured logging schema of usage data |
| US10047107B2 (en) | 2014-04-23 | 2018-08-14 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Small molecule analogs of E4orf1 |
| GB201910299D0 (en) * | 2019-07-18 | 2019-09-04 | Aouadi Myriam | Medical uses, methods and uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004004775T2 (de) * | 2004-08-12 | 2007-11-22 | Roche Diagnostics Gmbh | Verfahren zur Diagnose von Leberfibrose. |
| US20060045919A1 (en) | 2004-08-27 | 2006-03-02 | Samueli Institute | Homeopathic compositions and methods for the treatment of cancer |
| JP2008105945A (ja) * | 2005-02-07 | 2008-05-08 | Ajinomoto Co Inc | アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物 |
| ES2472325T3 (es) * | 2005-11-30 | 2014-06-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Gen y proteína del adenovirus 36 E4 orf 1 y sus usos |
| WO2007120362A2 (en) * | 2005-12-27 | 2007-10-25 | Obetech, Llc | Adipogenic adenoviruses as a biomarker for disease |
| JP2008273938A (ja) * | 2007-03-30 | 2008-11-13 | Shiseido Co Ltd | アディポネクチン産生促進剤 |
-
2011
- 2011-07-08 EP EP11741354.2A patent/EP2590665B1/en not_active Not-in-force
- 2011-07-08 TW TW100124173A patent/TWI531650B/zh not_active IP Right Cessation
- 2011-07-08 KR KR1020137001869A patent/KR101831638B1/ko not_active Expired - Fee Related
- 2011-07-08 CN CN201180033866.7A patent/CN103052397B/zh not_active Expired - Fee Related
- 2011-07-08 JP JP2013518858A patent/JP5965397B2/ja not_active Expired - Fee Related
- 2011-07-08 ES ES11741354.2T patent/ES2550962T3/es active Active
- 2011-07-08 NZ NZ606236A patent/NZ606236A/en not_active IP Right Cessation
- 2011-07-08 WO PCT/US2011/043338 patent/WO2012006512A1/en not_active Ceased
- 2011-07-08 CA CA2803787A patent/CA2803787C/en not_active Expired - Fee Related
- 2011-07-08 US US13/178,986 patent/US8951980B2/en not_active Expired - Fee Related
- 2011-07-08 AU AU2011274537A patent/AU2011274537B9/en not_active Ceased
-
2015
- 2015-01-06 US US14/590,262 patent/US20170340699A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130100262A (ko) | 2013-09-10 |
| JP5965397B2 (ja) | 2016-08-03 |
| JP2013531681A (ja) | 2013-08-08 |
| AU2011274537A1 (en) | 2013-02-14 |
| KR101831638B1 (ko) | 2018-02-23 |
| TWI531650B (zh) | 2016-05-01 |
| AU2011274537B9 (en) | 2017-02-23 |
| CN103052397B (zh) | 2017-09-19 |
| WO2012006512A1 (en) | 2012-01-12 |
| EP2590665A1 (en) | 2013-05-15 |
| CA2803787A1 (en) | 2012-01-12 |
| US20170340699A1 (en) | 2017-11-30 |
| TW201217529A (en) | 2012-05-01 |
| CA2803787C (en) | 2018-12-04 |
| AU2011274537B2 (en) | 2016-12-15 |
| HK1185261A1 (en) | 2014-02-14 |
| US20120027845A1 (en) | 2012-02-02 |
| ES2550962T3 (es) | 2015-11-13 |
| EP2590665B1 (en) | 2015-09-16 |
| US8951980B2 (en) | 2015-02-10 |
| CN103052397A (zh) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012019168A3 (en) | Engineered nucleic acids and methods of use thereof | |
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| NZ605420A (en) | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway | |
| WO2012087742A3 (en) | Methods and compositions suitable for managing blood glucose in animals | |
| MX2019000586A (es) | Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd). | |
| WO2012006421A3 (en) | Diagnosis and treatment of breast cancer | |
| IL224048B (en) | Antiganic composition comprising whole killed or attenuated pathogenic eschrichia coli ( e.coli) cells for intradermal or subcutaneous administration for treating a human patient for crohn's disease | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| PH12013501877A1 (en) | Nutritional compositions including branched chain fatty acids and methods of using same | |
| MY152033A (en) | Anti-siglec-15 antibody | |
| TN2011000263A1 (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| NZ627372A (en) | Clostridium histolyticum enzymes and methods for the use thereof | |
| IN2015DN02729A (enExample) | ||
| WO2013169864A3 (en) | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| IN2014DN06920A (enExample) | ||
| GEP20196969B (en) | New therapeutical composition containing apomorphine as active ingredient | |
| MX2009012922A (es) | Vacunacion intradermica de un peptido del virus del papiloma humano. | |
| AR082312A1 (es) | Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos | |
| SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| NZ594347A (en) | Antibodies against human tweak and uses thereof | |
| NZ629004A (en) | Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor | |
| MX2013005820A (es) | Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos. | |
| EA201591095A1 (ru) | Белок slurp-1 для применения в лечении глазных болезней | |
| UA104484C2 (uk) | Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2016 BY COMPUTER PACKAGES INC Effective date: 20150701 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2017 BY COMPUTER PACKAGES INC Effective date: 20160618 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2018 BY COMPUTER PACKAGES INC Effective date: 20170620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2019 BY DAVIES COLLISON CAVE PTY LTD Effective date: 20180629 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2020 BY DAVIES COLLISON CAVE PTY LTD Effective date: 20190701 |
|
| LAPS | Patent lapsed |